Search Result

Results for "

mutant+strains

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (1) Antibiotic (2) ATP Synthase (1) Bacterial (6) Cytochrome P450 (1) Dengue Virus (1) Drug Isomer (1) FGFR (1) Flavivirus (1) Fluorescent Dye (1) G-quadruplex (1) HBV (1) HCV (3) HCV Protease (3) HIV (18) Potassium Channel (2) PROTACs (1) Ras (1) Reverse Transcriptase (13) SARS-CoV (1) Virus Protease (2)
By Research Areas:	Cancer (2) Infection (33)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-157403

Jun12682 1 Publications Verification	Virus Protease SARS-CoV	Infection
Jun12682 is an orally active SARS-CoV-2 papain-like protease (PL ^pro) inhibitor, with a K_i value of 37.7 nM and an EC₅₀ value of 1.1 μM in the FlipGFP PL ^pro assay. Jun12682 has efficacy in hindering PL ^pro both deubiquitination and deISGylation, with K_i values of 63.5 and 38.5 nM, respectively. Jun12682 exhibits resistance in multiple PL ^pro mutant strains, and its enzymatic activity is comparable to that of the wild-type. Jun12682 can be used for the study of the SARS-CoV-2 .

HY-152161

HIV-1 inhibitor-51	HIV Reverse Transcriptase	Infection
HIV-1 inhibitor-51, a non-nucleoside reverse transcriptase inhibitor (NNRTI), exhibits outstanding antiviral activity against WT HIV-1 (IIIB) and a panel of mutant strains. HIV-1 inhibitor-51 has high binding affinity (K_D=2.50 μM) and inhibitory activity (IC₅₀=0.03 μM) to WT HIV-1 RT. HIV-1 inhibitor-51 has EC₅₀s of 2.22-53.3 nM for mutant strains (L100I, K103N, Y181C, Y188L, E138K, F227L + V106A, RES056) .

HY-152160

HIV-1 inhibitor-50	HIV Reverse Transcriptase	Infection
HIV-1 invistor-50 is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that targets HIV-1 reverse transcriptase (RT) (IC₅₀=50 nM). HIV-1 inhibitor-50 shows significant antiviral activity, with EC₅₀s of 2.22-53.3nM against HIV-1 IIIB and its mutant strains .

HY-15352

BMS 561390 DPC 083	Reverse Transcriptase HIV	Infection
BMS 561390 (DPC 083) is an orally available non-nucleoside reverse transcriptase inhibitor (NNRTI) with broad inhibitory effects on wild-type HIV-1 and mutant strains .

HY-175351

HIV-1-IN-83	HIV Reverse Transcriptase	Infection
HIV-1-IN-83 (Compound 18E) is a HIV-1 non-nucleoside reverse transcriptase inhibitor with an IC₅₀ of 0.45 μM for wild-type HIV-1 non-nucleoside reverse transcriptase. HIV-1-IN-83 has potent antiviral activity against both HIV-1 wild-type and mutant strains and improves antidrug resistance for Y188L and RES056 mutant strains. HIV-1-IN-83 has no significant toxicity up to 11.088 μM .

HY-P1974

FR 901379 WF11899A	Antibiotic	Infection
FR901379 (WF11899A) is a novel echinocandin-type lipopeptide antibiotic. FR901379 is primarily produced by mutant strain M-7 of Coleophoma empetri F-11899 (FERM BP-2635) .

HY-129943

Benzothiohydrazide	Bacterial	Infection
Benzothiohydrazide is an analogue of anti–tubercular agent Isoniazid. Benzothiohydrazide exhibits anti–tubercular activity, with MICs of 132 μM and 264 μM for M. tuberculosis wild type (H37Rv) and clinical mutant strains (IC₁ and IC₂) .

HY-163110

NNRT-IN-2	HIV Reverse Transcriptase	Infection
NNRT-IN-2 (compound 7w) is an orally available non-nucleoside reverse transcriptase inhibitor (NNRTI) with broad inhibitory effects on wild-type HIV-1 and mutant strains. NNRT-IN-2 inhibits HIV-1 reverse transcriptase with an EC₅₀ of 22 nM. NNRT-IN-2 is insensitive to CYP and hERG and has good safety and pharmacokinetic characteristics .

HY-174417

NNRT-IN-10	Reverse Transcriptase HIV Potassium Channel Cytochrome P450	Infection
NNRT-IN-10 is a potent, selective and orally active non-nucleoside HIV-1 reverse transcriptase (NNRTI) inhibitor with with an EC₅₀ values ranging from 1.16 to 18.3 nM for HIV and its mutant strains. NNRT-IN-10 exhibits good pharmacokinetic properties and favorable safety profiles. NNRT-IN-10 can be used for the study of AIDS, caused by HIV-1 .

HY-19932

MK-2748	HCV Protease HCV	Infection
MK-2748 is a hepatitis C virus (HCV) NS3/4a protease inhibitor. MK-2748 exhibits broad-spectrum and potent antiviral activity, with nanomolar-level activity against all genotypes (gt1a-gt6) (IC₅₀ < 0.115 nM), showing only slightly weaker activity against gt3a (1.212 nM), and maintaining high inhibitory activity against drug-resistant mutant strains such as gt1b R155K (IC₅₀ = 0.032 nM) and D168Y (IC₅₀ = 0.057 nM). MK-2748 can be used in the research of HCV infection .

HY-N14782

10-Decarbomethoxyaclacinomycin A	Antibiotic Bacterial	Infection Cancer
10-Decarbomethoxyaclacinomycin A is an anthracycline antibiotic can be produced by Streptomyces galilaeus MA144-Mlt mutant strain KE303. 10-Decarbomethoxyaclacinomycin A has antibacterial activities .

HY-151938

Reverse transcriptase-IN-3	HIV	Infection
Reverse transcriptase-IN-3 is a pyrimidine-5-carboxamide derivative, acts as an inhibitor of HIV-1. Reverse transcriptase-IN-3 shows potent activity against the HIV-1 wild-type and mutant strains .

HY-175491

HIV-1-IN-85	HIV Reverse Transcriptase	Infection
HIV-1-IN-85 is an orally active HIV-1 inhibitor (IC₅₀ = 72 nM). HIV-1-IN-85 exhibits strong inhibitory activity against wild-type (WT) HIV-1 and NNRTI-resistant single mutant strains (L100I, K103N, Y181C, Y188L, E138K) and moderate efficacy against double mutant strains (F227L+V106A, RES056). HIV-1-IN-85 shows good in vivo safety in ICR mice. HIV-1-IN-85 can be used for the study of HIV-1 infection .

HY-160678

InhA-IN-7	Bacterial	Infection
InhA-IN-7 (Compound 11) is a Triclocan (HY-B1119) derivative with inhibitory activity towards enoyl-acyl carrier protein reductase (InhA) with an IC₅₀ of 96 nM. InhA-IN-7 inhibits proliferations of Mycobacterium tuberculosis wildtype and mutant strains with MICs ranging from 19 to 75 μM .

HY-114956

AT-61	HBV	Infection
AT-61 is a non nucleoside HBV replication inhibitor. AT-61 prevents the capsid formation of pre genomic RNA, resulting in the production of empty capsids. AT-61 has the activity of drug-resistant mutant strains. AT-61 can be used for research on hepatitis B virus infection .

HY-149928

NNRT-IN-1	HIV	Infection
NNRT-IN-1 (compound 8r) is a potent non-nucleoside reverse transcriptase (NNRT) inhibitor featuring significantly anti-resistance efficacy. NNRT-IN-1 inhibits the wild-type HIV-1 and five *mutant strains* with EC₅₀s in the nanomolar range. NNRT-IN-1 displays favorable pharmacokinetic properties .

HY-167642

(Z)-Rilpivirine (Z)-R278474; (Z)-TMC278; (Z)-DB08864	Drug Isomer HIV Reverse Transcriptase	Infection
(Z)-Rilpivirine ((Z)-R278474) is the (Z)-isomer of Rilpivirine (HY-10574). Rilpivirine is an effective and selective diarylpyrimidine (DAPY) non-nucleoside reverse transcriptase inhibitor (NNRTI). It exhibits potent antiviral activity against both wild-type HIV (EC₅₀ = 0.4 nM) and mutant strains (EC₅₀ = 0.1-2.0 nM) .

HY-146746

HIV-1 inhibitor-19	HIV	Infection
HIV-1 inhibitor-19 is a potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI). HIV-1 inhibitor-19 maintains its inhibitory activity against L100I, K103N and V106A/ F227L mutant strains with EC₅₀s of 7.3 nM, 9.2 nM and 21.0 nM, respectively.

HY-172408

NNRT-IN-6	Reverse Transcriptase HIV	Infection
NNRT-IN-6 (Compound 13a) is the non-nucleoside reverse transcriptase inhibitor (NNRT) for HIV-1 reverse transcriptase (HIV-1 RT) with IC₅₀ of 0.41 μM. NNRT-IN-6 inhibits HIV-1 wildtype and mutant strains L100I, K103N, Y181C, Y188L, E138K, F227L/V106A and RES056 with EC₅₀ of 6.2-250 nM .

HY-162720

NNRT-IN-4	HIV Potassium Channel Reverse Transcriptase	Infection
NNRT-IN-4 (Compound 10p) is an inhibitor for non-nucleoside reverse transcriptase (NNRT) with an IC₅₀ of 0.713 µM for HIV-1 RT. NNRT-IN-4 exhibits antiviral efficacy, inhibits HIV-1 wildtype and mutant strains with EC₅₀ of 6-63 nM. NNRT-IN-4 exhibits a slight inhibitory activities against hERG (IC₅₀=25.9 µM) and CYP enzymes (IC₅₀>50 µM). NNRT-IN-4 exhibits good tolerability and safety in mice (2 g/kg) .

HY-178031

HIV-1-IN-87	HIV Reverse Transcriptase	Infection
HIV-1-IN-87 (Compound 11x) is a dual-site HIV-1 inhibitor targeting the non-nucleoside reverse transcriptase inhibitor binding pocket (NNIBP) and its adjacent site (NNIAS). HIV-1-IN-87 has potent antiviral activities against wild-type and mutant strains (such as L100I, K103N and Y181C) (EC₅₀: 4.1-150 nM). HIV-1-IN-87 can be used for HIV-1 infections like acquired immune deficiency syndrome (AIDS) research .

HY-169920

HIV-1 inhibitor-79	HIV Reverse Transcriptase	Infection
HIV-1 inhibitor-79 (Compound 3k) is an HIV inhibitor that exhibits significant inhibitory activity against HIV-1 and its common mutant strains (with IC₅₀ values of 1.9, 1.9, 8.7, and 11 nM against HIV-1, K103, L100I, and E138K, respectively), and has low cytotoxicity and a high selectivity index (CC₅₀ = 21.95 μM, SI = 11478). Additionally, HIV-1 inhibitor-79 also shows antiviral activity against HIV-2, with an EC₅₀ value of 6.14 μM, and significantly inhibits the activity of HIV-1 reverse transcriptase (IC₅₀ = 25 nM) .

HY-155046

FGFR4-IN-14	FGFR	Cancer
FGFR4-IN-14 (Compound 27i) is a FGFR4 inhibitor (IC₅₀: 2.4 nM. FGFR4-IN-14 inhibits the proliferation of V550L and N535K mutant strains, with IC₅₀s of 21 nM, 2.5 nM, 171 nM against huh7, BaF3/ETV6-FGFR4-V550L and BaF3/ETV6-FGFR4-N535K cells respectively. FGFR4-IN-14 has potent antitumor efficacy in the Huh7 xenograft model. FGFR4-IN-14 can be used for research of hepatocellular carcinoma (HCC) .

HY-146019A

HIV-1 inhibitor-25	HIV	Infection
HIV-1 inhibitor-25 (compound R-12a) is a highly potent HIV-1 reverse transcriptase, with an IC₅₀ value of 0.1061 μM. HIV-1 inhibitor-25 has high antiretroviral activity against WT HIV-1 with an EC₅₀ of 13.6 nM, and exhibits relatively low cytotoxicity with a CC₅₀ of 33.13 μM in MT-4 cells. HIV-1 inhibitor-25 also has inhibitory activity against HIV-1 mutant strains (L100I, K103N, Y181C, Y188L, E138K, F227L+V106A) with EC₅₀ of 0.1961 ~ 5.8136 μM. HIV-1 inhibitor-25 can be used for researching AIDS .

HY-108029

Deldeprevir sodium ACH-2684 sodium; Neceprevir sodium	HCV HCV Protease	Infection
Deldeprevir (ACH-2684; Neceprevir) sodium is a HCV NS3/4A protease inhibitor and resistance inhibitor. Deldeprevir sodium exhibits activity against wild-type genotype 1a and 1b HCV, including mutant strains resistant to other NS3 protease inhibitors. Deldeprevir sodium blocks the emergence of HCV mutant strains resistant to ACH-3422 in vitro, with enhanced efficacy when used in triple combination with ACH-3422 and ACH-3102 (HY-124182). Deldeprevir sodium shows additive antiviral potency when combined with ACH-3422, and exerts antiviral activity against HCV replicons carrying ACH-3102. Deldeprevir sodium is applicable to research related to hepatitis C .

HY-180149

PRP020	ATP Synthase Bacterial	Infection
PRP020 is a potent and specific inhibitor of mycobacterial ATP synthase. PRP020 does not inhibit acidification driven by succinate. PRP020 exihibits MIC₉₅ against M. tuberculosis of 2 μM, and it remains active against most drug-resistant mutant strains. PRP020 is highly safe and can be used in anti-tuberculosis research .

HY-115516

BI-1388	HCV HCV Protease Ras	Infection
BI-1388 is a macrocyclic acylsulfonamide-based HCV NS3-4A protease inhibitor. BI-1388 inhibits clinically relevant drug-resistant mutant strains (KRAS ^D168V gt 1b and KRAS ^R155K gt 1a) and exhibits high liver distribution. BI-1388 is applicable for the research of HCV infection .

HY-181713

Antibiofilm agent-19	Bacterial G-quadruplex	Infection
Antibiofilm agent-19 is an antibiofilm agent with iron-chelating activity. Antibiofilm agent-19 potently inhibits biofilm formation by wild-type PAO1 and the hyper-biofilm mutant strain PAO1-ΔwspF. Antibiofilm agent-19 promotes the formation of c-di-GMP G-quadruplexes and disrupts iron acquisition systems. It can be used in studies on antibacterial adjuvants .

HY-183551

Antitubercular agent-59		Infection
Antitubercular agent-59 is an orally active antitubercular agent with an IC₅₀ of 51 nM against Mycobacterium tuberculosis H37Rv. Antitubercular agent-59 inhibits growth of Bedaquiline (HY-14881)-resistant Rv0678^G12C mutant strains. Antitubercular agent-59 exerts bactericidal activity in chronic tuberculosis mouse models with 1-Aminobenzotriazole (HY-103389) coadministration .

HY-179437

anti-HIV agent 1	HIV	Infection
anti-HIV agent 1 (compound 10i) is a potent antiviral agent with anti-HIV activity (IC₅₀ = 10.6 nM). anti-HIV agent 1 exhibits moderate to no inhibitory activity against RT mutant strains, but maintains their activity against wild-type viruses. anti-HIV agent 1 strongly shows dual inhibition of the viral attachment and reverse transcriptase phases of the viral life cycle. anti-HIV agent 1 can be used for HIV infection research .

HY-181920

RPG-01-132	PROTACs Dengue Virus	Infection
RPG-01-132 is a DENV capsid protein PROTAC degrader, with a DC₅₀ of 2.4 μM. RPG-01-132 blocks viral assembly, eliminates viral particles, and interferes with the non-structural functions of capsid protein. RPG-01-132 exhibits significant antiviral activity against all four DENV serotypes and the ST148 (HY-121663)-resistant DENV2 mutant strain. RPG-01-132 is applicable to research related to dengue virus infection .

HY-D3192

CDy11	Fluorescent Dye Bacterial Amyloid-β	Infection
CDy11 is a fluorescent probe and amyloid-binding dye (λ_ex=590 nm; λ_em=612 nm), with a K_a of 29 μM for Pseudomonas aeruginosa Fap. CDy11 specifically recognizes amyloid fibrils in bacterial biofilms and exhibits significantly enhanced fluorescence upon binding to the target. CDy11 shows no staining effect on amyloid-deficient mutant strains, planktonic cells or protein monomers. CDy11 supports in vivo imaging of Pseudomonas aeruginosa biofilms in mouse implant and corneal infection models. CDy11 is widely used in studies of Staphylococcus aureus biofilm infections, dental caries, and Pseudomonas aeruginosa-associated implant and corneal infections .

HY-181034

NNRT-IN-15	Reverse Transcriptase HIV	Infection
NNRT-IN-15 (Compound 16a) is a potent non-nucleoside reverse transcriptase (NNRT) inhibitor. NNRT-IN-15 shows an EC₅₀ of 3 nM for WT HIV-1 and inhibits seven mutant strains (L100I, K103N, Y181C, etc.) (EC₅₀ = 8.2-43.4 nM). NNRT-IN-15 has low cytotoxicity against MT-4 cells (CC₅₀ = 196.46 μM). NNRT-IN-15 also inhibit WTHIV-1RT and hERG with IC₅₀ values of 0.7599 μM and 27.455 μM. NNRT-IN-15 can be used for research of HIV-1 infection .

HY-181991

IRBM-Z-2	Virus Protease Flavivirus	Infection
IRBM-Z-2 is a non-competitive, orally active Zika virus (ZIKV) NS2B-NS3 protease inhibitor, with IC₅₀ values of 0.04 μM and 3.1 μM against the wild-type and I156T mutant strains, respectively. IRBM-Z-2 exhibits broad-spectrum anti-flavivirus potential, with IC₅₀ values of 2.1 μM and 0.09 μM against the NS2B-NS3 proteases of dengue virus 2 (DENV2) and West Nile virus (WNV), respectively. IRBM-Z-1 inhibits ZIKV replication and alleviates virus-induced cytopathic effects. IRBM-Z-1 can be used in studies related to ZIKV infection .

Cat. No.	Product Name

HY-L940

Antiviral Lead-like compound library	5,813 compounds
Owing to the widespread transmission and frequent mutation of viral diseases, as well as the continuous emergence of new viruses and drug-resistant strains, antiviral drug development is facing increasingly stringent requirements. Antiviral compound libraries serve as important tools for drug screening, mechanism research and development, enabling the discovery and investigation of various antiviral drugs. These compounds act through diverse antiviral mechanisms, targeting key steps in viral replication, assembly and invasion. They exert antiviral effects by inhibiting viral nucleic acid synthesis, blocking viral protein processing, and preventing viral binding to host cells. This library covers various types of antiviral compounds, including nucleosides, non-nucleosides, protease inhibitors and integrase inhibitors. It supports research on influenza virus, herpes virus, hepatitis virus, emerging respiratory viruses and other pathogens, and enables high-throughput screening of novel antiviral candidates to rapidly identify potential active compounds against diverse viruses. It also facilitates mechanistic studies to elucidate drug-target interactions and viral resistance mechanisms, and supports the screening of effective compounds against mutant strains for research on viral variation and drug resistance. This antiviral library consists of 6,804 compounds with lead-like physicochemical properties. The core sources of the compounds include analogs of known antiviral molecues with a similarity score ≥ 0.6. MCE has collected more than 1450 antiviral molecules. As a small-molecule collection with both activity potential and structural modifiability, it provides strong support for antiviral drug research and development.

Antiviral Lead-like compound library

5,813 compounds

Owing to the widespread transmission and frequent mutation of viral diseases, as well as the continuous emergence of new viruses and drug-resistant strains, antiviral drug development is facing increasingly stringent requirements. Antiviral compound libraries serve as important tools for drug screening, mechanism research and development, enabling the discovery and investigation of various antiviral drugs.

These compounds act through diverse antiviral mechanisms, targeting key steps in viral replication, assembly and invasion. They exert antiviral effects by inhibiting viral nucleic acid synthesis, blocking viral protein processing, and preventing viral binding to host cells. This library covers various types of antiviral compounds, including nucleosides, non-nucleosides, protease inhibitors and integrase inhibitors. It supports research on influenza virus, herpes virus, hepatitis virus, emerging respiratory viruses and other pathogens, and enables high-throughput screening of novel antiviral candidates to rapidly identify potential active compounds against diverse viruses. It also facilitates mechanistic studies to elucidate drug-target interactions and viral resistance mechanisms, and supports the screening of effective compounds against mutant strains for research on viral variation and drug resistance.

This antiviral library consists of 6,804 compounds with lead-like physicochemical properties. The core sources of the compounds include analogs of known antiviral molecues with a similarity score ≥ 0.6. MCE has collected more than 1450 antiviral molecules. As a small-molecule collection with both activity potential and structural modifiability, it provides strong support for antiviral drug research and development.

Cat. No.	Product Name	Type

HY-D3192

CDy11	Fluorescent Dyes
CDy11 is a fluorescent probe and amyloid-binding dye (λ_ex=590 nm; λ_em=612 nm), with a K_a of 29 μM for Pseudomonas aeruginosa Fap. CDy11 specifically recognizes amyloid fibrils in bacterial biofilms and exhibits significantly enhanced fluorescence upon binding to the target. CDy11 shows no staining effect on amyloid-deficient mutant strains, planktonic cells or protein monomers. CDy11 supports in vivo imaging of Pseudomonas aeruginosa biofilms in mouse implant and corneal infection models. CDy11 is widely used in studies of Staphylococcus aureus biofilm infections, dental caries, and Pseudomonas aeruginosa-associated implant and corneal infections .

CDy11

Fluorescent Dyes

CDy11 is a fluorescent probe and amyloid-binding dye (λ_ex=590 nm; λ_em=612 nm), with a K_a of 29 μM for Pseudomonas aeruginosa Fap. CDy11 specifically recognizes amyloid fibrils in bacterial biofilms and exhibits significantly enhanced fluorescence upon binding to the target. CDy11 shows no staining effect on amyloid-deficient mutant strains, planktonic cells or protein monomers. CDy11 supports in vivo imaging of Pseudomonas aeruginosa biofilms in mouse implant and corneal infection models. CDy11 is widely used in studies of Staphylococcus aureus biofilm infections, dental caries, and Pseudomonas aeruginosa-associated implant and corneal infections .

Cat. No.	Product Name	Target	Research Area

HY-P1974

FR 901379 WF11899A	Antibiotic	Infection
FR901379 (WF11899A) is a novel echinocandin-type lipopeptide antibiotic. FR901379 is primarily produced by mutant strain M-7 of Coleophoma empetri F-11899 (FERM BP-2635) .

FR 901379 WF11899A	Microorganisms Antibiotics Other Antibiotics Source Classification	Antibiotic
FR901379 (WF11899A) is a novel echinocandin-type lipopeptide antibiotic. FR901379 is primarily produced by mutant strain M-7 of Coleophoma empetri F-11899 (FERM BP-2635) .

10-Decarbomethoxyaclacinomycin A	Microorganisms Antibiotics Other Antibiotics Source Classification	Antibiotic Bacterial
10-Decarbomethoxyaclacinomycin A is an anthracycline antibiotic can be produced by Streptomyces galilaeus MA144-Mlt mutant strain KE303. 10-Decarbomethoxyaclacinomycin A has antibacterial activities .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

mutant+strains

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Peptides

NaturalProducts

Natural
Products